Orphan Indications for CD19 Redirected Autologous T Cells — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Orphan Indications for CD19 Redirected Autologous T Cells — Stella

Home/Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL/

View on ClinicalTrials.gov

Recruiting

Back to Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Key details

Phase

Safety & dosing

Sponsor

Stephan Grupp MD PhD

Collaborators

University of Pennsylvania

Enrollment target

~133 participants

Started

March 2020

Primary completion

March 2028

Age range

0 Years – 29 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.